| Chimeric antigen receptor T cells for sustained remissions in leukemia SL Maude, N Frey, PA Shaw, R Aplenc, DM Barrett, NJ Bunin, A Chew, ... New England Journal of Medicine 371 (16), 1507-1517, 2014 | 6630 | 2014 |
| Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia SL Maude, TW Laetsch, J Buechner, S Rives, M Boyer, H Bittencourt, ... New England Journal of Medicine 378 (5), 439-448, 2018 | 6283 | 2018 |
| Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia DL Porter, BL Levine, M Kalos, A Bagg, CH June New England Journal of Medicine 365 (8), 725-733, 2011 | 4950 | 2011 |
| Chimeric antigen receptor–modified T cells for acute lymphoid leukemia SA Grupp, M Kalos, D Barrett, R Aplenc, DL Porter, SR Rheingold, ... New England Journal of Medicine 368 (16), 1509-1518, 2013 | 4546 | 2013 |
| T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia M Kalos, BL Levine, DL Porter, S Katz, SA Grupp, A Bagg, CH June Science translational medicine 3 (95), 95ra73-95ra73, 2011 | 3441 | 2011 |
| Chimeric antigen receptor T cells in refractory B-cell lymphomas SJ Schuster, J Svoboda, EA Chong, SD Nasta, AR Mato, Ö Anak, ... New England Journal of Medicine 377 (26), 2545-2554, 2017 | 2112 | 2017 |
| Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia DL Porter, WT Hwang, NV Frey, SF Lacey, PA Shaw, AW Loren, A Bagg, ... Science translational medicine 7 (303), 303ra139-303ra139, 2015 | 2100 | 2015 |
| A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma DM O’Rourke, MLP Nasrallah, A Desai, JJ Melenhorst, K Mansfield, ... Science translational medicine 9 (399), eaaa0984, 2017 | 2026 | 2017 |
| Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV P Tebas, D Stein, WW Tang, I Frank, SQ Wang, G Lee, SK Spratt, ... New England Journal of Medicine 370 (10), 901-910, 2014 | 1879 | 2014 |
| Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia JA Fraietta, SF Lacey, EJ Orlando, I Pruteanu-Malinici, M Gohil, S Lundh, ... Nature medicine 24 (5), 563-571, 2018 | 1870 | 2018 |
| CRISPR-engineered T cells in patients with refractory cancer EA Stadtmauer, JA Fraietta, MM Davis, AD Cohen, KL Weber, E Lancaster, ... Science 367 (6481), eaba7365, 2020 | 1645 | 2020 |
| Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma GP Linette, EA Stadtmauer, MV Maus, AP Rapoport, BL Levine, L Emery, ... Blood, The Journal of the American Society of Hematology 122 (6), 863-871, 2013 | 1440 | 2013 |
| Engineered T cells: the promise and challenges of cancer immunotherapy AD Fesnak, CH June, BL Levine Nature reviews cancer 16 (9), 566-581, 2016 | 1343 | 2016 |
| Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics CG Brunstein, JS Miller, Q Cao, DH McKenna, KL Hippen, J Curtsinger, ... Blood, The Journal of the American Society of Hematology 117 (3), 1061-1070, 2011 | 1330 | 2011 |
| Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia DT Teachey, SF Lacey, PA Shaw, JJ Melenhorst, SL Maude, N Frey, ... Cancer discovery 6 (6), 664-679, 2016 | 1237 | 2016 |
| NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma AP Rapoport, EA Stadtmauer, GK Binder-Scholl, O Goloubeva, DT Vogl, ... Nature medicine 21 (8), 914-921, 2015 | 1116 | 2015 |
| Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies GL Beatty, AR Haas, MV Maus, DA Torigian, MC Soulen, G Plesa, ... Cancer immunology research 2 (2), 112-120, 2014 | 1055 | 2014 |
| Global manufacturing of CAR T cell therapy BL Levine, J Miskin, K Wonnacott, C Keir Molecular therapy Methods & clinical development 4, 92-101, 2017 | 979 | 2017 |
| Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells JA Fraietta, CL Nobles, MA Sammons, S Lundh, SA Carty, TJ Reich, ... Nature 558 (7709), 307-312, 2018 | 969 | 2018 |
| Decade-long leukaemia remissions with persistence of CD4+ CAR T cells JJ Melenhorst, GM Chen, M Wang, DL Porter, C Chen, MKA Collins, ... Nature 602 (7897), 503-509, 2022 | 959 | 2022 |
Carl JuneUniversity of PennsylvaniaVerified email at upenn.edu
